



(51) International Patent Classification:

A61P 25/00 (2006.01) *A61P 1/00* (2006.01)
A61K 31/454 (2006.01) *C07D 413/12* (2006.01)

(21) International Application Number:

PCT/JP2012/002042

(22) International Filing Date:

23 March 2012 (23.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2011-065067 23 March 2011 (23.03.2011) JP

(71) Applicant (for all designated States except US):

RAQUALIA PHARMA INC. [JP/JP]; 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi, 4702341 (JP).

(72) Inventor; and

(75) **Inventor/Applicant (for US only):** **TAKAHASHI,
Nobuyuki** [JP/JP]; c/o **RAQUALIA PHARMA INC.**, 2,
Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi, 4702341
(JP).

(74) **Agent:** **IWATANI, Ryo;** KEIHAN Dojima Bldg. 3F, 1-31,
Dojima 2-chome, Kita-ku, Osaka-shi, Osaka 5300003 (JP).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** A 5-HT₄ RECEPTOR AGONIST AS A PROKINETIC AGENT

[Fig. 1]



(57) **Abstract:** This invention relates to Compound A or a pharmaceutically acceptable salt thereof with 5-HT₄ agonistic activities, which is useful in the treatment of gastrointestinal diseases. This invention also relates to a pharmaceutical composition for the treatment of gastrointestinal diseases which comprises a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of gastrointestinal diseases in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject Compound A or a pharmaceutically acceptable salt thereof.